ursodiol

Disclaimer to the Online Edition

This Manual has been designed for use in the NICU at London Health Sciences Centre (LHSC), London, Ontario, Canada, and represents clinical practice at this institution. The information contained within the Manual may not be applicable to other centres. If users of this Manual are not familiar with a drug, it is recommended that the official monograph be consulted before it is prescribed and administered. Any user of this information is advised that the contributors, Editor and LHSC are not responsible for any errors or omissions, and / or any consequences arising from the use of the information in this Manual.

ursodiol

Indication

  • Treatment of cholestasis associated with parenteral nutrition or biliary atresia

Dosage Guidelines

  • 5-10 mg/kg/dose ORAL q8 hours

Administration

  • ORAL

Adverse Effects

  • Diarrhea, vomiting, constipation, flatulence, rash, increased serum glucose

Comments

  • Decrease in bilirubin should be seen within 2 weeks of therapy
  • Serum bilirubin, ALP, ALT, AST and GGT should be monitored at 2 weeks of therapy and at monthly intervals thereafter
  • Discontinue if serum levels of bilirubin and liver enzymes increase.  This may indicate hepatic toxicity.  Lithocholic acid is a liver-toxic metabolite of ursodiol that is formed in the gut and detoxified through sulfation in the liver.

Supplied As

  • 50 mg/mL oral suspension
References
  1. LexiComp Sick Kids
  2. LexiComp Pediatric and Neonatal
  3. Neofax